Batiraxcept
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis[1][2][3].
Product Specifications
CAS Number
2268717-61-7
Product Name Alternative
AVB-500; AVB-S6-500
UNSPSC
12352203
Target
Akt; p38 MAPK; PI3K; TAM Receptor
Type
Inhibitory Antibodies
Related Pathways
MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/batiraxcept.html
Purity
99.91
Solubility
10 mM in DMSO
Smiles
[Batiraxcept]
Molecular Weight
(93.85 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
Axl
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![BCL2 Mouse Monoclonal Antibody [Clone ID: OTI9D3]](https://cdn.genprice.uk/products/937/68dd18b9061270361e90827b/imageurl/cf806591.webp)
(1-Oxo-1-((1-phenethylpiperidin-4-yl)(phenyl)amino)propan-2-yl)carbonic Acid Ethyl Ester
